NCT06235229View on ClinicalTrials.gov

A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

GC012F

GC012F is a BCMA/CD19 dual CAR product

Trial Locations (10)

100024

RECRUITING

Research Site, Beijing

102200

RECRUITING

Research Site, Beijing

110134

NOT_YET_RECRUITING

Research Site, Shenyang

200003

NOT_YET_RECRUITING

Research Site, Shanghai

201210

RECRUITING

Research Site, Shanghai

250117

RECRUITING

Research Site, Jinan

310003

NOT_YET_RECRUITING

Research Site, Hangzhou

325000

RECRUITING

Research Site, Wenzhou

430030

RECRUITING

Research Site, Wuhan

710004

NOT_YET_RECRUITING

Research Site, Xi'an

All Listed Sponsors
lead

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY